Your browser doesn't support javascript.
Monoclonal antibodies for treating COVID-19.
Pallotta, Andrea M; Kim, ChungYun; Gordon, Steven M; Kim, Alice.
  • Pallotta AM; Inpatient Pharmacy, Cleveland Clinic, Cleveland, OH pallota@ccf.org.
  • Kim C; DInpatient Pharmacy, Cleveland Clinic, Cleveland, OH.
  • Gordon SM; Department of Infectious Diseases, Respiratory Institute, Cleveland Clinic, Cleveland, OH.
  • Kim A; Director, Inpatient Care Coordination and LTACH Program, Department of Medical Operations, Cleveland Clinic, Cleveland, OH.
Cleve Clin J Med ; 2021 Feb 17.
Article in English | MEDLINE | ID: covidwho-1088980
ABSTRACT
Bamlanivimab and casirivimab-imdevimab are novel virus-neutralizing monoclonal antibodies authorized to treat mild to moderate COVID-19 in outpatients at risk for progression to severe disease. Treatment early in the disease may show efficacy in reducing progression to severe disease, although safety and efficacy data are limited. They are not authorized for hospitalized patients with more advanced disease.
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Journal subject: Medicine Year: 2021 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Journal subject: Medicine Year: 2021 Document Type: Article